AIMLogo.jpg
Hemispherx Highlights Year-To-Date Progress, Outlines Key Objectives
December 19, 2017 08:30 ET | Hemispherx Biopharma, Inc.
Letter to Shareholders Posted on Website Revenue Up, Burn Rate Down Dramatically; Progress Cited with FDA Discussions on Ampligen; Manufacturing Facility for FDA-Approved Alferon N Fully Repaired;...
AIMLogo.jpg
Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15, 2016
November 10, 2016 08:30 ET | Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its 2016 third quarter financial...
AIMLogo.jpg
Hemispherx Biopharma's Judgment Unanimously Affirmed Against Cato Capital
August 26, 2015 10:00 ET | AIM ImmunoTech Inc.
WILMINGTON, Del., Aug. 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that on Friday the Third Circuit Court of Appeals upheld the...